News
BioXcel Therapeutics KOL Roundtable Highlights Unmet Need in Alzheimer’s Agitation, BXCL501 Data
1+ hour, 46+ min ago (605+ words) Posted by Kim Johansen on Mar 1st, 2026 Mehta referenced previously announced results from a Phase III pivotal study of BXCL501 for the acute treatment of agitation in Alzheimer's dementia, stating that the product candidate was well-tolerated and met its primary efficacy endpoint....
BioAge Labs Touts Oral NLRP3 Inhibitor BGE-102 Data, Eyes CV Study and Retinal Expansion
9+ hour, 40+ min ago (335+ words) Posted by Danessa Lincoln on Mar 1st, 2026 On pharmacology, Fortney highlighted what she described as potential best-in-class potency, including an IC90 of 1.8 nM in a human ex vivo whole-blood stimulation assay. She said the company has shown 24-hour IC90 coverage at 60 mg once…...
Best Chinese Stocks To Follow Today – February 26th
1+ day, 1+ hour ago (81+ words) Posted by Tristan Rich on Mar 1st, 2026 We are a Hong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired therapies and products. We offer a wide range of beauty, wellness, and postpartum services and products rooted and influenced by the principles…...
Design Therapeutics Highlights GeneTAC Pipeline, FA Data Timeline and DM1 Dosing Plans at Oppenheimer Conference
1+ day, 2+ hour ago (593+ words) Posted by Sarita Garza on Feb 28th, 2026 Shah also noted the company is working on a preclinical program in Huntington's disease. In FA, Shah said patients produce normal frataxin, but at low levels due to abnormally long GAA repeats in the…...
Climb Bio Highlights 2025 Data Catalysts, CD19 and APRIL Programs at Oppenheimer Conference
1+ day, 5+ hour ago (595+ words) Posted by Danessa Lincoln on Feb 28th, 2026 Climb Bio (NASDAQ:CLYM) outlined its strategy and upcoming clinical milestones during a fireside chat at Oppenheimer's 36th Annual Healthcare Life Sciences Conference, with Chief Medical Officer Edgar Charles and CFO Susan Altschuller joining analyst…...
Kymera Therapeutics Pivots to Immunology, Highlights KT-621 Data, Starts IRF5 Dosing; Runway to 2029
1+ day, 6+ hour ago (250+ words) Posted by Michael Walen on Feb 28th, 2026 Kymera Therapeutics (NASDAQ:KYMR) executives highlighted a sharpened strategic focus on immunology and inflammation at Oppenheimer's 36th Annual Healthcare Conference, emphasizing progress in its STAT6 degrader KT-621, the start of clinical dosing for its IRF5 program, and…...
Aethlon Medical Highlights Hemopurifier Cancer Trial Progress, Key March DSMB Milestone at Conference
1+ day, 21+ hour ago (191+ words) Posted by Michael Walen on Feb 28th, 2026 Frakes explained that the Hemopurifier can be connected to existing blood-pumping infrastructure commonly found in hospitals and clinics worldwide, including dialysis machines, plasmapheresis machines, and CRRT systems. Treatment sessions are typically about four hours,…...
Best Healthcare Stocks To Follow Now – February 27th
2+ day, 3+ hour ago (75+ words) Posted by Tristan Rich on Feb 27th, 2026 FIGS, Inc. operates as a direct-to-consumer healthcare apparel and lifestyle company in the United States and internationally. It designs and sells healthcare apparel and scrubwear and non-scrubwear offerings, such as outerwear, underscrubs, footwear, compression…...
IDEAYA Biosciences Teases End-of-March Data for Darovasertib Combo at Citi Oncology Summit
3+ day, 8+ hour ago (279+ words) Posted by Michael Walen on Feb 26th, 2026 He noted a formal OS interim analysis is planned for the beginning of 2027. In the discussion, Beaupre suggested that around 30% of OS events is a threshold at which stakeholders may begin to have more…...
Avalo Therapeutics Highlights AVTX-009 HS Phase II Catalyst, Cash Runway at Oppenheimer Conference
4+ day, 14+ min ago (387+ words) Posted by Kim Johansen on Feb 26th, 2026 Avalo's lead program, AVTX-009, is an anti-IL-1" monoclonal antibody being evaluated in moderate-to-severe HS. Neil described IL-1" as central to the inflammatory process in HS and highlighted the disease's neutrophilic features. He said HS lesions…...